top of page
toc.png

Clinical Approach to MCAS Diagnosis and Cutaneous Mastocytosis

References

  1. Valent, P., et al., Updated Diagnostic Criteria and Classification of Mast Cell Disorders:  A Consensus Proposal. Hemasphere, 2021. 5(11): p. e646. 

  2. Valent, P., et al., Definitions, criteria and global classification of mast cell disorders with  special reference to mast cell activation syndromes: a consensus proposal. Int Arch  Allergy Immunol, 2012. 157(3): p. 215-25. 

  3. Gulen, T., et al., Selecting the Right Criteria and Proper Classification to Diagnose Mast  Cell Activation Syndromes: A Critical Review. J Allergy Clin Immunol Pract, 2021. 9(11):  p. 3918-3928. 

  4. Giannetti, A., et al., Mast Cell Activation Disorders. Medicina (Kaunas), 2021. 57(2). 

  5. Luskin, K.T., A.A. White, and J.J. Lyons, The Genetic Basis and Clinical Impact of  Hereditary Alpha-Tryptasemia. J Allergy Clin Immunol Pract, 2021. 9(6): p. 2235-2242. 

  6. Lyons, J.J., et al., Mendelian inheritance of elevated serum tryptase associated with atopy  and connective tissue abnormalities. J Allergy Clin Immunol, 2014. 133(5): p. 1471-4.

  7. Guerrerio, P., Druey, K., Lyons, J., Metcalfe, DD., Mathias, R. Hereditary alpha  trytpasemia and hereditary alpha tryptasemia syndrome FAQ. 2018. DOI:  https://www.niaid.nih.gov/research/hereditary-alpha-tryptasemia-faq. 

  8. Valent, P., Mast cell activation syndromes: definition and classification. Allergy, 2013.  68(4): p. 417-24. 

  9. Valent, P., et al., Global Classification of Mast Cell Activation Disorders: An ICD-10- CM-Adjusted Proposal of the ECNM-AIM Consortium. J Allergy Clin Immunol Pract,  2022. 10(8): p. 1941-1950. 

  10. Weiler, C.R., et al., AAAAI Mast Cell Disorders Committee Work Group Report: Mast  cell activation syndrome (MCAS) diagnosis and management. J Allergy Clin Immunol,  2019. 144(4): p. 883-896. 

  11. Valent, P., et al., Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell  Activation Syndrome. J Allergy Clin Immunol Pract, 2019. 7(4): p. 1125-1133 e1.

  12. Gulen, T. and C. Akin, Idiopathic Anaphylaxis: a Perplexing Diagnostic Challenge for  Allergists. Curr Allergy Asthma Rep, 2021. 21(2): p. 11. 

  13. Weiler, C.R., Mast Cell Activation Syndrome: Tools for Diagnosis and Differential  Diagnosis. J Allergy Clin Immunol Pract, 2020. 8(2): p. 498-506. 

  14. Valent, P., et al., Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for  Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. Int Arch  Allergy Immunol, 2019. 180(1): p. 44-51. 

  15. Pongdee, T. and M. Castells, Elevated Tryptase: Conditions and Pitfalls. J Allergy Clin  Immunol Pract, 2022. 10(9): p. 2436-2437. 

  16. Mateja, A., et al., Defining baseline variability of serum tryptase levels improves  accuracy in identifying anaphylaxis. J Allergy Clin Immunol, 2022. 149(3): p. 1010-1017  e10. 

  17. Sargur, R., et al., Raised tryptase without anaphylaxis or mastocytosis: heterophilic  antibody interference in the serum tryptase assay. Clin Exp Immunol, 2011. 163(3): p.  339-45. 

  18. Valent, P., et al., Refined diagnostic criteria and classification of mast cell leukemia  (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol, 2014.  25(9): p. 1691-1700. 

  19. Valent, P., et al., Diagnosis, Classification and Management of Mast Cell Activation  Syndromes (MCAS) in the Era of Personalized Medicine. Int J Mol Sci, 2020. 21(23). 

  20. Valent, P., et al., Standards and standardization in mastocytosis: consensus statements on  diagnostics, treatment recommendations and response criteria. Eur J Clin Invest, 2007.  37(6): p. 435-53. 

  21. Akin, C. and P. Valent, Diagnostic criteria and classification of mastocytosis in 2014. Immunol Allergy Clin North Am, 2014. 34(2): p. 207-18. 

  22. Akin, C., Molecular diagnosis of mast cell disorders: a paper from the 2005 William  Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn, 2006. 8(4): p.  412-9. 

  23. Akin, C., P. Valent, and D.D. Metcalfe, Mast cell activation syndrome: Proposed  diagnostic criteria. J Allergy Clin Immunol, 2010. 126(6): p. 1099-104 e4. 

  24. Akin, C., Mast cell activation disorders. J Allergy Clin Immunol Pract, 2014. 2(3): p.  252-7 e1; quiz 258. 

  25. Carter, M.C., et al., Assessment of clinical findings, tryptase levels, and bone marrow  histopathology in the management of pediatric mastocytosis. J Allergy Clin Immunol,  2015. 136(6): p. 1673-1679 e3. 

  26. Carter, M.C., et al., Abnormal bone marrow histopathology in paediatric mastocytosis. Br  J Haematol, 2015. 168(6): p. 865-73. 

  27. Castells, M., D.D. Metcalfe, and L. Escribano, Diagnosis and treatment of cutaneous  mastocytosis in children: practical recommendations. Am J Clin Dermatol, 2011. 12(4):  p. 259-70. 

  28. Lange, M., et al., Clinical aspects of paediatric mastocytosis: a review of 101 cases. J Eur Acad Dermatol Venereol, 2013. 27(1): p. 97-102. 

  29. Schwartz, L.B., et al., Time course of appearance and disappearance of human mast cell  tryptase in the circulation after anaphylaxis. J Clin Invest, 1989. 83(5): p. 1551-5.

  30. Takeda, J., et al., Plasma N-methylhistamine concentration as an indicator of histamine  release by intravenous d-tubocurarine in humans: preliminary study in five patients by  radioimmunoassay kits. Anesth Analg, 1995. 80(5): p. 1015-7. 

  31. Nassiri, M., et al., Serum levels of 9alpha,11beta-PGF2 and cysteinyl leukotrienes are  useful biomarkers of anaphylaxis. J Allergy Clin Immunol, 2016. 137(1): p. 312-314 e7. 

  32. Sampson, H., et al., Second symposium on the definition and management of  anaphylaxis: summary report--Second National Institute of Allergy and Infectious  Disease/Food Allergy and Anaphylaxis Network symposium. The Journal of allergy and clinical immunology, 2006. 117(2). 

  33. Pumphrey, R.S.H., Fatal posture in anaphylactic shock. Journal of Allergy and Clinical  Immunology, 2003. 112(2): p. 451-452. 

  34. D'Astous-Gauthier, K., et al., Beta-2 agonists may be superior to epinephrine to relieve  severe anaphylactic uterine contractions. The Journal of Allergy and Clin Immunol: In  Practice, 2021. 9(3): p. 1232-1241. 

  35. Meni, C., et al., Paediatric mastocytosis: a systematic review of 1747 cases. Br J  Dermatol, 2015. 172(3): p. 642-51. 

  36. Meni, C., et al., Paediatric mastocytosis: long-term follow-up of 53 patients with whole  sequencing of KIT. A prospective study. Br J Dermatol, 2018. 179(4): p. 925-932. 

  37. Ben-Amitai, D., A. Metzker, and H.A. Cohen, Pediatric cutaneous mastocytosis: a review  of 180 patients. Isr Med Assoc J, 2005. 7(5): p. 320-2. 

  38. Lanternier, F., et al., Phenotypic and genotypic characteristics of mastocytosis according  to the age of onset. PLoS One, 2008. 3(4): p. e1906. 

  39. Sotlar, K., et al., One-step detection of c-kit point mutations using peptide nucleic acid mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol,  2003. 162(3): p. 737-46. 

  40. Brockow, K., et al., Anaphylaxis in patients with mastocytosis: a study on history, clinical  features and risk factors in 120 patients. Allergy, 2008. 63(2): p. 226-32. 

  41. Leung, A.K.C., J.M. Lam, and K.F. Leong, Childhood Solitary Cutaneous Mastocytoma:  Clinical Manifestations, Diagnosis, Evaluation, and Management. Curr Pediatr Rev,  2019. 15(1): p. 42-46. 

  42. Sandru, F., et al., Cutaneous Mastocytosis in Childhood-Update from the Literature. J  Clin Med, 2021. 10(7). 

  43. Czarny, J., et al., Cutaneous mastocytosis treatment: strategies, limitations and  perspectives. Advances in Dermatology and Allergology, 2018. 35(6): p. 541-545.

toc.png
bottom of page